サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：免疫チェックポイント阻害剤の世界市場-2022-2029
市場調査レポート
商品コード
1153824

免疫チェックポイント阻害剤の世界市場-2022-2029

Global Immune Checkpoint Inhibitors Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
免疫チェックポイント阻害剤の世界市場-2022-2029
出版日: 2022年11月15日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

免疫チェックポイント阻害剤の世界市場は、2021年に311億5,029万米ドルとなり、2029年には1324億2741万米ドルに達すると予測され、予測期間（2022～2029年）のCAGRは14.58%で成長するとされています。

免疫チェックポイント阻害剤は、抗体でできた薬剤で、がん細胞に対する免疫システムの攻撃を解き放ちます。チェックポイント阻害剤は、免疫系の攻撃に対するがんの主要な防御手段の一つを克服しようとするものです。チェックポイント阻害剤は、がん細胞の正常なタンパク質やT細胞のタンパク質をブロックします。その結果、T細胞ががん細胞として認識するのを妨げていた目隠しが取り除かれ、がん細胞に対する免疫システムの攻撃につながるのです。

市場力学

これらの免疫チェックポイント阻害剤に対する需要の増加、臨床試験での良好な結果、研究開発費の増加、新規製品の上市の増加が市場成長の原動力になると予想されます。

新規製品の上市と免疫チェックポイント阻害剤デバイスの需要の増加が市場成長の原動力となります。

免疫チェックポイント阻害剤の世界市場は、ヘルスケア業界における免疫チェックポイント阻害剤に対する需要の急増、製品上市の増加、臨床試験での良好な結果、従来の化学療法単独に比べた多くの利点が主な要因となっています。臨床段階にある様々な薬剤が、様々ながんの治療において良好な結果を示しています。例えば、2021年10月、AstraZenecaのHIMALAYA第III相試験で、高レベルの良好な結果が報告されました。全身療法を受けていない切除不能な肝細胞がん患者の1次治療として、トレメリムマブとイムフィンジの単回投与は、ソラフェニブと比較して臨床的に有意な全生存期間の延長を示しました。この新しい投与法は、STRIDEレジメンとして知られています。

様々な最新技術の進歩があり、免疫チェックポイント阻害剤の薬剤の上市が増加し、需要も増加しています。例えば、2022年6月にロシュが非小細胞肺がんの治療薬としてテセントリク（アテゾリズマブ）を欧州委員会から承認されたと発表しています。テセントリクは、PD-L1＞50％の腫瘍発現で再発リスクの高い非小細胞肺がん患者に対して、完全切除と化学療法（プラチナ製剤）の後に行う術後補助治療です。

免疫チェックポイント阻害剤治療に関連する高コストが市場成長の妨げとなります。

チェックポイント阻害剤に関連する治療費の高さは、市場の成長を抑制します。2021年12月に発表されたJournal of Clinical Pathwaysのレポート「Cost of extended use of immune checkpoint inhibitors in first-line non-small cell lung cancer」によると、免疫チェックポイント阻害剤の平均コストは約14万8431ドル（約1,000万円）です。ニボルマブ/イピリムマブのコストは54万4,696ドル程度でした。

COVID-19の影響分析

パンデミックは、世界の金融への期待、オペレーション、危機対応戦略にマイナスの影響を及ぼしています。市場参入企業は、研究市場を活用し、パンデミックに対抗する最先端のアイテムを生み出すことで、長期的・短期的な成長戦略を変えようとしています。COVID-19が業界に害を与えても、事業運営のためにできるだけ早くバックアッププランを準備し、実行することが重要です。様々なコラボレーションや合併が世界中で起こっており、市場の成長を後押ししています。例えば、2022年1月、アストラゼネカはスコーピオン・セラピューティクスと提携し、標的が難しいがんタンパク質に対する精密医薬品の研究開発・販売を行い、がん治療を変革する可能性があります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 新規製品上市の増加
      • 免疫チェックポイント阻害剤に対する需要の増加
    • 抑制要因
      • 阻害剤に関連する高コスト
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • アンメットニーズ
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 薬剤クラス別

  • プログラム死受容体1阻害剤（PD-1）
    • ペムブロリズマブ
    • セミプリマブ
    • ニボルマブ
    • その他
  • プログラム死リガンド1阻害剤（PDL-1）
    • アベルマブ
    • アテゾリズマブ
    • デュルバルマブ
  • 細胞傷害性Tリンパ球抗原4阻害剤（CTLA-4）
    • イピリムマブ
  • リンパ球活性化遺伝子3阻害剤（LAG-3）
    • レラトリマブ

第8章 アプリケーション別

  • 肺がん
  • 血液がん
  • 膀胱がん
  • ホジキンリンパ腫
  • メラノーマ
  • 乳がん
  • 子宮頸がん
  • その他

第9章 流通チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • AstraZeneca PLC
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Bristol-Myers Squibb
  • Roche Holdings AG
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Merck & Co., Inc
  • Ono Pharmaceutical Co.
  • Kite Pharma, Inc（Gilead company）
  • F. Hoffmann-La Roche AG

第13章 免疫チェックポイント阻害剤の世界市場-DataM

目次
Product Code: DMPH867

Market Overview

The global immune checkpoint inhibitors market was valued at US$ 31,150.29 million in 2021 and is estimated to reach US$ 132,427.41 million by 2029, growing at a CAGR of 14.58% during the forecast period (2022-2029).

The immune checkpoint inhibitor is a drug made of antibodies that unleashes an immune system attack on cancer cells. Checkpoint inhibitors seek to overcome one of cancer's primary defenses against an immune system attack. Checkpoint inhibitors block normal proteins in cancer cells or the proteins in T cells. The result is removing the blinders that prevented T cells from recognizing them as cancerous, leading to an immune system assault on them.

Market Dynamics

The increasing demand for these immune checkpoint inhibitors, positive results in clinical trials, the increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and demand for immune checkpoint inhibitor devices drive market growth.

The global market for immune checkpoint inhibitors is primarily driven by the surge in demand for immune checkpoint inhibitor drugs in the healthcare industry, the rising number of product launches, positive results from clinical trials, and the many advantages over traditional chemotherapy alone. Various drugs in the clinical stage are showing good results in the treatment of various cancers. For instance, in Oct 2021, AstraZeneca' HIMALAYA phase III trial reported positive high-level results. The single dose of tremelimumab and Imfinzi showed a clinically significant overall survival benefit compared with sorafenib for 1st line treatment for unresectable hepatocellular carcinoma patients who haven't gotten systemic therapy. This new dose is known as the STRIDE regimen.

Various latest technological advancements are taking place, and the number of immune checkpoint inhibitors drug launches is increasing, increasing the demand as well. For instance, in Jun 2022, Roche announced the approval of Tecentriq (atezolizumab) for treating non-small cell lung cancer by the European Commission. Tecentriq is an adjuvant treatment that follows full resection and chemotherapy (platinum-based) for non-small cell lung cancer patients with high recurrence risk with PD-L1>50% tumor expression.

High costs associated with immune checkpoint inhibitors therapy will hamper the market's growth.

The high cost of therapies related to checkpoint inhibitors will restrain the market growth. According to the Journal of Clinical Pathways report published in Dec 2021, titled "Cost of extended use of immune checkpoint inhibitors in first-line non-small cell lung cancer," the average cost of immune checkpoint inhibitors is around $148,431. Cost of nivolumab/ipilimumab were around $544,696.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the industry, preparing and implementing backup plans as soon as possible for business operations is crucial. Various collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Jan 2022, AstraZeneca collaborated with Scorpion Therapeutics to research, develop and market precision medicines against the hard-to-target cancer proteins, potentially transforming the oncology treatment.

Segment Analysis

The programmed death receptor 1 inhibitor (PD-1) drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The programmed death receptor 1 inhibitor (PD-1) segment is the highest market holder in the global immune checkpoint inhibitors market. The programmed death receptor 1 inhibitor (PD-1) share accounted for the largest market because of its novel, innovative drug launches, an increasing number of pipelines and increasing prevalence of cancer. PD-1 is a checkpoint protein on the T cells (immune cells), which plays the role of an "off switch" that prevents T cells from attacking the body's other cells. It controls it at the time of its attachment with PD-L1, a kind of protein on a few normal and cancerous cells. When the binding occurs, the T-cell gets the message not to kill the cell. Few cancerous cells have a huge amount of PD-L1, which helps them to hide from immune attacks easily. The monoclonal antibodies targeting PD-1 inhibit the binding of PD-1 with PD-L1, ultimately increasing the immune response against cancerous cells. According to the WHO report 2022, cancer caused approximately ten million deaths globally, making it the major cause globally in 2020. The most common reason for cancer death was lung cancer accounting for around 1.80 million deaths. The novel development of these PD-1 inhibitors will benefit various cancer treatments. Increasing regulatory approvals of these PD-1 inhibitors are increasing market growth. For instance, in Aug 2021, GlaxoSmith Kline announced the approval of Jemparli (dostarlimab), a PD-1 immune checkpoint inhibitor for patients with advanced endometrial cancer and mismatch repair deficient recurrence.

Geographical Analysis

North America holds the largest market share of the global immune checkpoint inhibitors market.

North America dominates the global immune checkpoint inhibitors market, primarily attributed to the increasing number of partnerships or collaborations between companies, the rising demand for immune checkpoint inhibitor drugs, and novel studies. Furthermore, factors including growing expenditure on research and development and the increasing incidence of cancer will likely enhance the growth of the region's immune checkpoint inhibitors market.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments are taking place based in this region. For instance, in Sep 2022, AstraZeneca announced the approval of Imfinzi (durvalumab) by the United States Food and Drug Administration for treating metastatic or locally advanced biliary tract cancer patients with chemotherapy. This approval was based on a phase III trial of TOPAZ-1, where Imfinzi and chemotherapy minimized the death risk by 20% compared to chemotherapy alone.

Competitive Landscape

The immune checkpoint inhibitors market is highly competitive with local and global companies. AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc, Key players contributing to the market's growth Ono Pharmaceutical Co., Kite Pharma, Inc (Gilead company), F. Hoffmann-La Roche AG and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Apr 2020, Kite, Gilead Company and oNKo-innate announced their collaboration for research in cancer immunotherapy. Both companies entered in 2-year collaboration to support the development of next-gen drug therapies and engineered cell therapies focusing on natural killer cells (NK).

AstraZeneca PLC:

Overview:

AstraZeneca is a science-led, bio-pharmaceutical company that researches, develops and markets prescription medicines. It was established in 1999 and is headquartered in Cambridge, United Kingdom.

Product Portfolio:

Imfinzi (Durvalumab): This is an immune checkpoint inhibitor, a human immunoglobulin G1 monoclonal antibody used as immunotherapy for certain cancers. It inhibits the interaction between programmed cell death ligand 1 with programmed death receptor 1.

Key Development: In Aug 2022, AstraZeneca announced that it had completely acquired TeneoTwo Inc. This acquisition includes TeneoTwo's TNB-486, evaluated in B-cell non-Hodgkin lymphoma, phase I clinical stage CD19/CD3 T-cell engager.

The global immune checkpoint inhibitors market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing demand for immune checkpoint inhibitor drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with these inhibitors
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Programmed Death Receptor 1 Inhibitor (PD-1) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Pembrolizumab
    • 7.2.4. Cemiplimab
    • 7.2.5. Nivolumab
    • 7.2.6. Others
  • 7.3. Programmed Death Ligand 1 Inhibitors (PDL-1)
    • 7.3.1. Avelumab
    • 7.3.2. Atezolizumab
    • 7.3.3. Durvalumab
  • 7.4. Cytotoxic T Lymphocyte Antigen 4 Inhibitors (CTLA-4)
    • 7.4.1. Ipilimumab
  • 7.5. Lymphocyte Activation Gene 3 Inhibitors (LAG-3)
    • 7.5.1. Relatlimab

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Lung Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Blood Cancer
  • 8.4. Bladder Cancer
  • 8.5. Hodgkin Lymphoma
  • 8.6. Melanoma
  • 8.7. Breast Cancer
  • 8.8. Cervical Cancer
  • 8.9. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. AstraZeneca PLC
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb
  • 12.3. Roche Holdings AG
  • 12.4. Novartis AG
  • 12.5. Pfizer Inc.
  • 12.6. Sanofi
  • 12.7. Merck & Co., Inc
  • 12.8. Ono Pharmaceutical Co.
  • 12.9. Kite Pharma, Inc (Gilead company)
  • 12.10. F. Hoffmann-La Roche AG

LIST NOT EXHAUSTIVE

13. Global Immune Checkpoint Inhibitors Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us